Germany’s Merck KGAAhas augmented production capacity for its pharmaceutical business in China by opening a new €170m ($180m) drug plant in Nantong dedicated to the manufacture of medicines on China’s Essential Drug List (EDL).
Following an initial €80m investment announced in 2013, the firm injected an additional €90m into the Nantong site, now home to the second-largest pharma manufacturing facility for Merck worldwide.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?